Stay updated on Nivolumab vs. Everolimus in RCC: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.

Latest updates to the Nivolumab vs. Everolimus in RCC: Clinical Trial page
- Check6 days agoChange DetectedThe access-denied page is replaced by the study record, displaying details about the nivolumab-versus-everolimus trial, including its design, eligibility criteria, outcomes, and study history.SummaryDifference100%

- Check13 days agoChange DetectedThe site footer revision label changed from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check27 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.1 to v3.7.2. The page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check48 days agoChange DetectedAccess to the study page is blocked, displaying a 403 Forbidden error. The page shows standard site chrome and a Home link, indicating the study record is not currently accessible.SummaryDifference0.5%

Stay in the know with updates to Nivolumab vs. Everolimus in RCC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.